# Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

> **NCT06660511** · EARLY_PHASE1 · RECRUITING · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 5 (estimated)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** Disitamab Vedotin in Combination With Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT06660511
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-10-15
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660511, "Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06660511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*